Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming

p16抑制诱导mTORC1介导的核苷酸代谢重编程

阅读:2
作者:Raquel Buj ,Chi-Wei Chen ,Erika S Dahl ,Kelly E Leon ,Rostislav Kuskovsky ,Natella Maglakelidze ,Maithili Navaratnarajah ,Gao Zhang ,Mary T Doan ,Helen Jiang ,Michael Zaleski ,Lydia Kutzler ,Holly Lacko ,Yiling Lu ,Gordon B Mills ,Raghavendra Gowda ,Gavin P Robertson ,Joshua I Warrick ,Meenhard Herlyn ,Yuka Imamura ,Scot R Kimball ,David J DeGraff ,Nathaniel W Snyder ,Katherine M Aird

Abstract

Reprogrammed metabolism and cell cycle dysregulation are two cancer hallmarks. p16 is a cell cycle inhibitor and tumor suppressor that is upregulated during oncogene-induced senescence (OIS). Loss of p16 allows for uninhibited cell cycle progression, bypass of OIS, and tumorigenesis. Whether p16 loss affects pro-tumorigenic metabolism is unclear. We report that suppression of p16 plays a central role in reprogramming metabolism by increasing nucleotide synthesis. This occurs by activation of mTORC1 signaling, which directly mediates increased translation of the mRNA encoding ribose-5-phosphate isomerase A (RPIA), a pentose phosphate pathway enzyme. p16 loss correlates with activation of the mTORC1-RPIA axis in multiple cancer types. Suppression of RPIA inhibits proliferation only in p16-low cells by inducing senescence both in vitro and in vivo. These data reveal the molecular basis whereby p16 loss modulates pro-tumorigenic metabolism through mTORC1-mediated upregulation of nucleotide synthesis and reveals a metabolic vulnerability of p16-null cancer cells. Keywords: BRAF; cancer metabolism; cell cycle; melanoma; nevi; pancreatic cancer; pentose phosphate pathway; ribonucleotide reductase M2; ribose-5-phosphate isomerase A; senescence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。